Executive Director, Theranostics Platform Enablement
Novartis
Summary
The Executive Director, Theranostics Platform Enablement will be accountable for shaping and aligning cross-functional strategies that enable Novartis to sustain and expand Theranostics leadership. The role will strengthen the platform capabilities required to support Radioligand Therapy (RLT) leadership today while enabling future Radioligand Imaging (RLI)-supported growth, including patient identification, site readiness, access, referral flow, treatment capacity, and analytics-driven decision making.
Job description
Job Description Summary
The Executive Director, Theranostics Platform Enablement will be accountable for shaping and aligning cross-functional strategies that enable Novartis to sustain and expand Theranostics leadership. The role will strengthen the platform capabilities required to support Radioligand Therapy (RLT) leadership today while enabling future Radioligand Imaging (RLI)-supported growth, including patient identification, site readiness, access, referral flow, treatment capacity, and analytics-driven decision making.
The individual will work across the Theranostics ecosystem to align priorities, guide strategic workstreams, and address barriers that limit eligible patients from being identified, referred, accessed, and treated with appropriate RLT medicines. The role will operate in close collaboration with the Integrated Product Strategy team, RLT and RLI general management teams, and stakeholders across Commercial, Medical, Market Access, Patient Services, Legal, Operations, Finance, and Strategy. This leader will use analytics, account insights, and ecosystem trends to identify bottlenecks, prioritize interventions, inform senior leadership decisions, and support TA-level resource allocation.
Key Responsibilities
- Own and advance TA-critical Theranostics platform enablement strategies that support RLT leadership today, strengthen readiness for future RLI-supported growth and accelerate our commercial ambition
- Collaborate with and influence Commercial Execution, New Product Strategy, Marketing, Market Access, Patient Services, Medical, Legal, Operations, Finance, and Strategy to improve patient identification, referral flow, site readiness, treatment access, and customer experience
- Translate analytics, account insights, and ecosystem trends into prioritized actions that address bottlenecks across RLT and RLI pathways
- Drive TA-level prioritization, investment trade-off discussions, and resource alignment for Theranostics platform enablement in partnership with senior leadership and cross-functional governance forums
- Drive alignment and progress across high-priority strategic workstreams with senior stakeholder visibility, including treatment site access, capacity, patient flow, and launch readiness
- Oversee a budget of up to $40M dedicated to cross-functional initiatives that advance Theranostics platform enablement
- Lead and develop 2 Associate Directors (1 current, 1 planned for 2027), Theranostics Platform Enablement, while influencing matrixed teams to deliver against TA priorities
Essential Requirements
Education (minimum/desirable): College degree required, advanced degree preferred.
- Bachelor's Degree required. Advanced degree preferred
- 10+ years of relevant experience in pharmaceutical marketing/P&L function, consulting, investment banking, legal, or other relevant field
- Demonstrated ability to lead large-scale, cross-functional initiatives across Oncology, Radioligand Therapy, diagnostics, imaging, platform enablement, market access, patient services, analytics, or strategy
- Experience translating complex data, customer insights, and ecosystem dynamics into executive-level decisions and prioritized actions
- Proven ability to operate with ambiguity, urgency, and senior stakeholder visibility while driving alignment across matrixed teams
- Experience managing budgets, leading teams, and delivering high-impact initiatives with measurable business outcomes
- Radiopharmaceutical, RLT, RLI, diagnostics, imaging, or advanced therapeutic platform experience preferred
Requirements
- Bachelor's Degree required
- Advanced degree preferred
- 10+ years of relevant experience in pharmaceutical marketing/P&L function, consulting, investment banking, legal, or other relevant field
- Demonstrated ability to lead large-scale, cross-functional initiatives across Oncology, Radioligand Therapy, diagnostics, imaging, platform enablement, market access, patient services, analytics, or strategy
- Experience translating complex data, customer insights, and ecosystem dynamics into executive-level decisions and prioritized actions
- Proven ability to operate with ambiguity, urgency, and senior stakeholder visibility while driving alignment across matrixed teams
- Experience managing budgets, leading teams, and delivering high-impact initiatives with measurable business outcomes
- Radiopharmaceutical, RLT, RLI, diagnostics, imaging, or advanced therapeutic platform experience preferred
Benefits
- Health Benefits
- Life Insurance
- Disability Benefits
- 401(k) Matching
- Performance-Based Cash Incentive
- Annual Equity Awards
- Vacation
- Personal Days
- Holidays
- Other Leaves
Company overview
Novartis is a global pharmaceutical company headquartered in Basel, Switzerland, dedicated to reimagining medicine to improve and extend people's lives. As an innovative medicines company, Novartis focuses on developing high-value treatments that address society's greatest disease burdens through technology leadership in research and development. The company operates across five core therapeutic areas: cardiovascular, renal and metabolic diseases; immunology; neuroscience; oncology; and hematology. With a workforce of approximately 75,883 employees worldwide, Novartis reaches nearly 300 million patients across 118 countries. The company leverages advanced technology platforms including targeted protein degradation, cell therapy, gene therapy, radioligand therapy, and xRNA to develop breakthrough treatments. Novartis maintains a strong portfolio of oncology drugs and generics while continuously expanding its pipeline through strategic acquisitions and internal research. The company's commitment extends beyond drug development to ensuring global access to medical innovations through novel access approaches and patient assistance programs.